ResearcherDalian Medical UniversityNo recent work listed
Xueying Shi
Matched on ORCID iD 0000-0003-0384-560X; OpenAlex author ID A5044777574. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers
Papers 6
- A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo. Co-author DOI 10.1007/s10142-023-01158-1↗
- A network pharmacology-based investigation of emodin against pancreatic adenocarcinoma. Co-author DOI 10.1097/md.0000000000033521↗
- Identification and characterization of interferon-γ signaling-based personalized heterogeneity and therapeutic strategies in patients with pancreatic cancer. Co-author DOI 10.3389/fonc.2023.1227606↗
- 5-fluorouracil suppresses stem cell-like properties by inhibiting p38 in pancreatic cancer cell line PANC-1. First author DOI 10.5603/fhc.a2022.0004↗
- An immune-related lncRNA signature for the prognosis of pancreatic adenocarcinoma. Co-author DOI 10.18632/aging.203323↗
- The nine ADAMs family members serve as potential biomarkers for immune infiltration in pancreatic adenocarcinoma. Co-author DOI 10.7717/peerj.9736↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shilin Xia · 3 shared papers, 2020–2023 · strength 0.42
- Paper Identification and characterization of interferon-γ signaling-based personalized heterogeneity and therapeutic strategi… DOI 10.3389/fonc.2023.1227606↗
- Paper An immune-related lncRNA signature for the prognosis of pancreatic adenocarcinoma. DOI 10.18632/aging.203323↗
- Paper The nine ADAMs family members serve as potential biomarkers for immune infiltration in pancreatic adenocarcinoma. DOI 10.7717/peerj.9736↗
- Qihang Yuan · 2 shared papers, 2023 · strength 0.37
- Paper A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with exper… DOI 10.1007/s10142-023-01158-1↗
- Paper Identification and characterization of interferon-γ signaling-based personalized heterogeneity and therapeutic strategi… DOI 10.3389/fonc.2023.1227606↗
- Xu Chen · 2 shared papers, 2023 · strength 0.37
- Paper A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with exper… DOI 10.1007/s10142-023-01158-1↗
- Paper Identification and characterization of interferon-γ signaling-based personalized heterogeneity and therapeutic strategi… DOI 10.3389/fonc.2023.1227606↗
- Bing Qi · 2 shared papers, 2020–2021 · strength 0.24
- Han Liu · 2 shared papers, 2020–2021 · strength 0.24
- Cuixia Cao · 1 shared paper, 2022 · strength 0.19
- Jin Zhao · 1 shared paper, 2022 · strength 0.19
- Rui Liu · 1 shared paper, 2022 · strength 0.19
- Zhizhou Wang · 1 shared paper, 2023 · strength 0.18
- Fangyue Guo · 1 shared paper, 2023 · strength 0.18
- Dong Shang · 1 shared paper, 2023 · strength 0.18
- Dong Shang · 1 shared paper, 2023 · strength 0.18
- Shi-Lin Xia · 1 shared paper, 2023 · strength 0.17
- Qi Zhou · 1 shared paper, 2021 · strength 0.13
- Ji Li · 1 shared paper, 2021 · strength 0.13
- Yajun Gu · 1 shared paper, 2021 · strength 0.13
- Lei Yao · 1 shared paper, 2020 · strength 0.11
- Yuan Yuan Ma · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.